TNFRSF14 and cancer: Our study highlights a novel resistant mechanism to IFN exposure and PD-L1 blockade in cancer: Malignant cells under IFN-γ exposure in TME acquire intrinsic TNFRSF14 elevation, which leads to resistance to ICB.